# Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.

> **NCT00219388** · PHASE4 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 60 (—)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Levosimendan

## Key facts

- **NCT ID:** NCT00219388
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 60 (—)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219388, "Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00219388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*